Viemed Healthcare, Inc. · NASDAQ:VMD
Viemed Healthcare — Investor Presentation (August 2022)
24 slides from Viemed Healthcare's investor presentation, Aug 5, 2022
Slide 1: Leading the Healthcare Industry in Home Respiratory Care
Investor Presentation Leading the Healthcare Industry in Home Respiratory Care NASDAQ: VMD TSX: VMD.TO August 2022 Slide 1
Slide 2: Disclaimers and Other Important Information
DISCLAIMERS Disclaimers and Other Important Information This presentation (the “Presentation”) about Viemed Healthcare, Inc. (“Viemed”) is dated as of August 2022. It is information in a summary form and does not purport to be complete. The data contained herein is derived from various internal and
Slide 3: Viemed at a Glance
▪ Largest independent specialized provider of non-invasive ventilation (NIV) in the US home respiratory health care industry ▪ Highly profitable with a 40% CAGR in revenue growth since 2010 ▪ Service offering includes 24x7 in home respiratory care including specialized respiratory therapists and med
Slide 4: Our Journey
SLEEP MANAGEMENT FOUNDED Annual Revenues: $0.24M USD Respiratory DME specializing in CPAPS & Oxygen HSD Annual Revenues: $3.58M USD Home Sleep Delivered – Specializing in home sleep tests VENTILATOR EXPANSION Annual Revenues: $4.60M USD Non Invasive ventilator introduced to market PHM ACQUISITION An
Slide 5: Key Investment Consideration
Key Investment Consideration Specialized US based respiratory healthcare services company ▪ Focused on Chronic Obstructive Pulmonary Disease (COPD) and growing aging population ▪ $50 billion of annual healthcare cost in the U.S. spent on COPD Significant Market Growth Opportunity ▪ 10,000 baby boome
Slide 6: Current State of the Industry
Viemed Healthcare, Inc. | Investor Presentation $40.0 $40.6 $43.3 $44.9 $46.6 $48.7 $50.6 $51.9 $54.4 $57.0 $54.9 $58.2 $61.7 $65.4 $69.3 $73.5 $77.9 $82.6 $87.5 $92.8 $98.3 Current State of the Industry The Medicare population is growing Expenditures are expected to grow at a 6% CAGR from $54.9 bil
Slide 7: NIV Market Penetration
NIV Market Penetration 25 Million (estimated) people in the U.S. have COPD 2,500,000 or 10% have stage 4 COPD 1,250,000 or 50% of those with stage 4 COPD develop chronic respiratory failure becoming candidates for our therapy Approximately 70,000 Medicare beneficiaries on NIV service * Viemed Health
Slide 8: Product and Payor Mix
Product and Payor Mix Viemed Healthcare, Inc. | Investor Presentation Slide 8 Ventilation 70% Sleep 11% Oxygen 7% Other 12% Medicare 46% Medicaid 9% Commercial 23% HMO 11% Private/ Other 11% PRODUCT MIX 6/30/2022 PAYOR MIX 6/30/2022
Slide 9: The Viemed Solution
The Viemed Solution Registered Respiratory Therapists (RTs) assigned to each patient and on call 24X7 ▪ All RTs are COPD educators ▪ Assess and service medical equipment ▪ Overseen by pulmonologists on staff ▪ Behavioral health specialist support Each patient is given a customized in-home care plan
Slide 10: A Dedicated 24/7 Respiratory Therapist with all our Viemed products
A DEDICATED 24/7 RESPIRATORY THERAPIST with all our Viemed products Ventilators Sleep Therapy Oxygen Therapy Patient Engagement Percussion Vests Slide 10
Slide 11: Proven Organic Growth Strategy
Proven Organic Growth Strategy Location selection ▪ Based on high COPD rates ▪ Target hospitals and facilities with high readmission rates and near existing service area ▪ Leverage existing relationships and operate heavily in rural markets Unique lean deployment model ▪ No costly retail stores ▪ Sa
Slide 12: Published Research: Real world results
Published Research Real world results Viemed Healthcare, Inc. | Investor Presentation Slide 12 43% Relative mortality reduction if utilized within 0 - 7 days 11.6% Cost reduction if utilized within 0 – 7 days 7.2% Cost reduction if utilized within 0 – 15 days $5,484 Cost reduction if utilized within
Slide 13: Technology and Remote Care
Technology and Remote Care ▪ Mission of becoming a leading healthcare technology company coupled with high touch human interaction in the home ▪ Goal is to improve quality of life and length of time patients spend with loved ones ▪ Increase efficiency of clinicians through improved remote workflow a
Slide 14: Objectives for the Next Months
Objectives for the Next 24 Months ▪ Grow active patient base while entering new target states through geographic expansion ▪ Communicate findings from the growing number of research studies to referral sources and payors in order to save more lives and increase market penetration ▪ Diversify payor b
Slide 15: Financial Information
Financial Information Slide 15
Slide 16: Regulatory Update
Regulatory Update ▪ CMS has made improvements in the process of patients obtaining quality care (i.e. telehealth rules, relaxing face to face requirements, remote patient monitoring, etc.) ▪ Non-invasive vents removed from 2021competitive bidding program (3 year term) and competitive bidding program
Slide 17: Revenue Model
Revenue Model ▪ Monthly rental fee – reimbursed by insurance and covered by Medicare ▪ Uncapped rental contract for ventilators (69 % of 2Q22 revenue) ▪ Average monthly client revenue is ~US$950 (all providers paid same rate by Medicare) ▪ Pricing includes equipment rental, RT service, supplies and
Slide 18: Historical Financial Performance
0 1,000 2,000 3,000 4,000 5,000 6,000 7,000 8,000 9,000 10,000 Viemed Healthcare, Inc. | Investor Presentation Historical Financial Performance Active Vent Rental Patients 8,837 as of 6/30/22 $140,000,000 $120,000,000 $110,000,000 $100,000,000 $80,000,000 $60,000,000 $40,000,000 $20,000,000 $0 2018
Slide 19: Capital Markets Profile
Capital Markets Profile Viemed Healthcare, Inc. | Investor Presentation 38,221,990 & 37,242,642 Shares outstanding & fully diluted $21.9M 17% Insider beneficial ownership Cash on hand in USD Total LT debt in USD $4.2M Total staff 719 Market cap as of July 31, 2022: ~$300M (USD) Stock price as of Jul
Slide 20: Corporate Structure
Viemed Healthcare, Inc. | Investor Presentation Corporate Structure Viemed Healthcare Inc. (Canadian Parent Company Listed on NASDAQ & TSX) Viemed Inc. (Delaware Corporation/US Subsidiary) Sleep Management, LLC (US Sub- Louisiana) Home Sleep Delivered, LLC (US Sub- Louisiana) Viemed Clinical Service
Slide 21: Board of Directors
Board of Directors Viemed Healthcare, Inc. | Investor Presentation Casey Hoyt Chief Executive Officer and Director Randy Dobbs Chairman of the Board and Independent Director Todd Zehnder Chief Operating Officer and Director Nitin Kaushal Independent Director Bruce Greenstein Independent Director Tim
Slide 22: Investor Relations
Investor Relations: Glen Akselrod Bristol Capital IR glen@bristolir.com Tel: 905 326 1888 Slide 22
Slide 23: Appendix
VieMed | Appendix Live your Life
Slide 24: Reconciliation of Net Revenue and Adjusted EBITDA
Viemed Healthcare, Inc. | Investor Presentation 2018 2019 2020 2021 1H 2022 Reconciliation of Net Revenue(1) Revenue 64.5$ 80.3$ 131.3$ 117.1$ 65.6$ Bad Debt Expense (6.1) - - - - Net Revenue 58.4$ 80.3$ 131.3$ 117.1$ 65.6$ Reconciliation of Adjusted EBITDA(2) Net Income 9.5$ 8.5$ 31.5$ 9.1$ 2.7$ De
Viemed Healthcare — Investor Presentation (August 2022) on 6ix